Top Tweets for #Corcept

Aponia_Analytics

@AponiaAnalytics

7 months ago

$CORT #Corcept @US_FDA 🦉FDA turned down Corcept’s relacorilant, demanding more efficacy data for Cushing’s hypertension. Shares cratered 48%—and analysts warn fresh trials may be unavoidable. https://t.co/FbKDWe96yY

0

2

1

1

285

Patexia @Patexia

over 2 years ago

Corcept Therapeutics experienced a significant drop in its stock value by 27% on Tuesday following an unfavorable verdict in a patent infringement lawsuit against Teva Pharmaceutical Industries. https://t.co/CbsvplOQR0 #patent #anda #hatchwaxman #teva #corcept #pharmaceutical

Patexia's tweet photo. Corcept Therapeutics experienced a significant drop in its stock value by 27% on Tuesday following an unfavorable verdict in a patent infringement lawsuit against Teva Pharmaceutical Industries.

https://t.co/CbsvplOQR0

#patent #anda #hatchwaxman #teva #corcept #pharmaceutical https://t.co/ngCQFTqzAE

0

3

1

0

147

almost 3 years ago

✅ #Corcept Therapeutics agreed to settle $14 million with #investors to end the securities lawsuit over hiding that $CORT improperly paid doctors and inflated #Korlym revenue using illicit sales practices. https://t.co/tIkVnQ6SFT

0

3

1

1

404

over 3 years ago

$CORT settles for $14 million to resolve securities fraud lawsuit involving its brand-name version of the abortion pill, Korlym. #Corcept #Korlym #AbortionDrug #SecuritiesFraud #lSettlement

0

4

1

0

115

ISS Securities Class Action Services @iss_scas

over 3 years ago

#Corcept Therapeutics Incorporated and investors announced a $14 million tentative settlement. Allegations relate to an off-label scheme to expand the market for #Korlym beyond its #FDA-approved use for a narrow subset of Cushing’s Syndrome. Terms to follow. #classaction $CORT

0

3

0

0

199

Alan Leong @alanhobbes

about 4 years ago

#BioWatch Update - #Corcept $CORT - Q2-2022 - Trio of Clinical Results Coming. Read at: https://t.co/Gzt4WEay23

1

3

0

0

0

Alan Leong @alanhobbes

about 4 years ago

#BioWatch News' commentary on #Corcept's $CORT updated ovarian cancer results & pivotal trial design. Plus an added bonus: major Phase 2 ALS trial design. Read at: https://t.co/GEXJJMHzcx

0

2

0

0

0

Alan Leong @alanhobbes

about 4 years ago

BioWatch News' May 2022 Updates on #Corcept Therapeutics $CORT (https://t.co/W6u2m3LGrP) and #Capricor Therapeutics $CAPR (https://t.co/rek7z8yCPF). Enjoy!

0

3

0

0

0

Alan Leong @alanhobbes

over 4 years ago

#BioWatch commentary on #Corcept's $CORT ovarian cancer results and program update. Read at: https://t.co/pa6RRn84h4

0

2

0

0

0

Alan Leong @alanhobbes

almost 5 years ago

Our commentary on #Corcept $CORT's Q3-2021 report and Dutch Auction announcement: https://t.co/4IxbvprslG

1

2

1

0

0

Alan Leong @alanhobbes

about 5 years ago

#BioWatch comments on #Corcept's $CORT Q2-2021 (surprising) earnings and conference call. Read at: https://t.co/2pQBH6lia5

1

2

1

0

0

Alan Leong @alanhobbes

about 6 years ago

Biowatch comments on #prostatecancer study results with mifepristone + enzalutamide - $CORT #Corcept - read at https://t.co/Gn1x6ynrb6

0

3

0

0

0

Alan Leong @alanhobbes

about 6 years ago

#Biowatch Commentary on #Corcept $CORT - Pancreatic Cancer Trial - New IP - Clinical Updates - Cushing's Program Expansion - $Teva at-risk launch - read at https://t.co/S13VjJ9Qaz

0

4

1

0

0

Alan Leong @alanhobbes

over 6 years ago

#Biowatch comments on #Corcept's $CORT Q4-2019 Update at https://t.co/ji9lEWtcoi

1

3

1

0

0

Alan Leong @alanhobbes

over 6 years ago

#Biowatch commentary on #Corcept's $CORT preliminary Q4-2019 results & guidance. See https://t.co/UOn8Z9bf9K

0

3

2

0

0

Alan Leong @alanhobbes

over 7 years ago

#Corcept $CORT releases Q1-2019 results & guidance. @alanhobbes's commentary at https://t.co/ljFbW5vKKu

0

2

0

0

0

Alan Leong @alanhobbes

over 7 years ago

@alanhobbes briefly comments on updated clinical results of #Corcept's $CORT #relacorilant to treat #Cushing's syndrome. Read at https://t.co/FWgGLd4Fgd

0

2

0

0

0

Alan Leong @alanhobbes

over 7 years ago

@alanhobbes writes about #Corcept's $CORT Q4-2018 results and its changing story on metabolic syndrome at https://t.co/1eKLZIbV4s

0

6

2

0

0

Alan Leong @alanhobbes

over 7 years ago

@alanhobbes comments on #Corcept's $CORT preliminary FY2018 sales & guidance (https://t.co/XeF4dCcRG2) and new trials in antipsychotic weight-gain & NASH (https://t.co/q9ux6GWELe)

0

4

1

0

0

Alan Leong @alanhobbes

over 7 years ago

@alanhobbes and his updated thoughts about #Corcept $CORT and more at https://t.co/h8TEk7FSMa

0

1

0

0

0

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users